
usd feb pm et
summari compani primarili provid medic technolog product nich busi
price-to-earnings oper ep
base busi princip serv
stabl global health care sector histori
gener solid revenu profit growth howev
compani financi leverag remain higher
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
incorpor lift
target base
multipl ep
estim ep vs
surpass estim lower
ep initi
ep constant
currenc basi sale increas
million led growth
america oem asia
declin emea weak emea
partial due time phase
remain elev rel
histor level expect declin
compani finish transit facil
implement process improv
receiv day dso also elev
day vs day
due implement
ep greater
headwind expect /kevin huang cfa
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview teleflex incorpor engag develop manufactur suppli
single-us medic devic use hospit health care provid common diagnost
therapeut procedur critic care surgic applic sell product hospit
healthcar provid global combin direct sale forc distributor
product use numer market varieti procedur depend upon one
end market procedur seven report segment vascular north america
emea asia oem segment
tfx vascular north america segment offer product facilit varieti critic care therapi
applic product primarili consist tfx arrow brand cathet relat
devic cathet posit system intervent north america segment consist
product use intervent cardiologist intervent radiologist vascular surgeon vein
practic north america anesthesia north america segment compris compani north
american pain manag airway manag product product like tfx airway
manufactur develop sell comprehens rang surgic product use varieti
europ middl east africa emea asia segment design manufactur distribut medic
devic primarili use critic care surgic applic cardiac care gener serv hospit
health care provid home health specifi region oem segment design manufactur
suppli devic instrument medic devic manufactur tfx busi
includ immateri oper segment respiratory/urolog north america intervent urolog
north america latin america
industri dynam medic devic industri highli competit compet mani
compani rang small start-up enterpris compani larger establish
market character new product develop technolog chang requir compani
continu develop acquir new product technolog remain competit compet
primarili basi clinic superior innov featur enhanc patient benefit product
reliabl perform custom sale support cost effect major end market
hospitals/health care provid revenu medic devic manufactur home
health tfx major competitor includ plc becton dickinson compani boston
vascular solut inc vascular solut neotract medic devic compani
develop commerci urolift system minim invas medic devic treat lower
urinari tract symptom due benign prostat hyperplasia bph vascular solut medic
devic compani develop market clinic product use minim invas coronari
financi trend tfx revenu grew billion bolster recent acquisit
adjust ep compani grew year-over-year reflect five-year compound
annual growth rate compound-annual-growth-rate septemb compani low moder level
debt net debt capit leverag ratio net debt trailing-twelve-month ebitda
free cash flow million million
chairman board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra reiter hold opinion share teleflex incorpor
maintain target above-p
ep estim warrant premium due
recent acquir higher growth busi ep vs equal
estim lower ep initi
ep sale increas constant currenc cc
million driven cc growth intervent north america
segment million growth oem segment million
intervent urolog sale includ tfx urolift devic
million total sale continu see urolift key driver
sale growth especi recent posit data devic urolift shonin
approv japan also obtain pre-market approv pma fda
manta devic global market manta approxim million
expect slow limit launch /kevin huang cfa
incorpor lift target
above-p ep estim warrant
premium peer due recent acquir higher growth busi ep
vs higher estim lift ep
sale increas organ million
acquir neotract busi begin contribut organ
growth debut contribut revenu growth octob
neotract urolift system receiv approv market distribut
japan market approxim million men age
moder sever benign prostat hyperplasia bph symptom seen
physician symptom confid abil deliv
organ growth increas invest
neotract vascular solut support strong momentum /kevin huang cfa
analyst research note compani news
pm et cfra keep hold opinion share teleflex incorpor
lift target base multipl
ep estim ep vs
surpass estim lower ep
initi ep constant currenc basi sale
increas million led growth america
oem asia declin emea weak emea
partial due time phase certain distributor order
inventori level remain elev rel histor level
expect declin compani finish transit facil
implement process improv receiv day dso also elev
day vs day due implement
european medic devic regul tfx ep guidanc
project neg impact ep greater headwind
expect /kevin huang cfa
et cfra maintain hold opinion share teleflex incorpor
lift target base forward price-to-earnings
multipl ep estim ep
vs surpass estim recent oper margin
expans despit beat maintain ep estim
neg impact closur third-parti steril facil
constant currenc cc million led
america region revenu grew cc follow cc
growth emea asia oem sale inventori
day dsi increas day yoy day rais concern may
hold much inventori could pressur futur margin
manag note earn call increas tactic
move design enhanc custom servic increas safeti stock level
pm et cfra keep hold opinion share teleflex incorpor
rais target base forward price-to-earnings
multipl ep estim lift
multipl high end rang due increas confid
commerci execut ep vs fell short
estim lift ep sale
increas constant currenc cc million
expect driven impress cc growth america
million cc growth asia million strength asia
led sale growth china howev currenc continu strong
headwind asia neg impact sale slightli less
neg impact intervent urolog busi led
urolift product gener million sale reflect
cc yoy increas growth emea cc expect due
time certain order /kevin huang cfa
pm et cfra keep hold opinion share teleflex incorpor
lift target base above-p
multipl ep estim warrant
premium due recent acquir higher growth busi ep
vs beat consensu expect lift ep
ep sale increas
constant currenc cc million driven
solid cc growth america million cc growth asia
impress currenc neg impact
intervent urolog busi remain strong sale grew cc
million continu uptak urolift devic manag note
commerci team train urologist total
us intend roll-out urolift aim fulli convert
 physician base second-gener devic /kevin huang
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
